In:
Lupus, SAGE Publications, Vol. 29, No. 6 ( 2020-05), p. 599-606
Kurzfassung:
This study aimed to assess systematically the overall diagnostic value of urinary monocyte chemoattractant protein-1 (uMCP-1) in systemic lupus erythematosus (SLE) patients with active lupus nephritis (LN). Methods Articles from PubMed, Web of Science, EMBASE and Cochrane Library were retrieved up to 5 November 2019. Study quality was evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, and statistical analyses were performed. Results A total of seven original studies with 521 participants were included in this meta-analysis. The summary estimates were: sensitivity 0.89 (95% confidence interval (CI) 0.86–0.93), specificity 0.63 (95% CI 0.55–0.69), positive likelihood ratio 2.16 (95% CI 1.66–2.80), negative likelihood ratio 0.15 (95% CI 0.08–0.30), diagnostic odds ratio 19.40 (95% CI 7.24–51.96) and area under the curve 0.9042. Conclusion As a non-invasive biomarker, uMCP-1 has high diagnostic accuracy for active LN.
Materialart:
Online-Ressource
ISSN:
0961-2033
,
1477-0962
DOI:
10.1177/0961203320914372
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2020
ZDB Id:
2008035-9